Evelo Biosciences is a clinical‐stage biotechnology company focused on harnessing the power of the gut–immune axis to develop novel therapies for inflammatory and immuno‐oncology indications. The company’s proprietary platform, based on its Microbiome Immune Biology® core, seeks to identify and deliver naturally derived, single‐strain biologic candidates that can modulate systemic immune responses through the gut. Evelo’s approach centers on oral, non‐colonizing, microbe‐derived therapeutic candidates designed to engage immune pathways in a predictable and controllable manner.
The company’s lead programs include EDP1815, targeting inflammatory diseases such as psoriasis, atopic dermatitis and other Th1/Th17‐mediated conditions, and EDP1503, which is being evaluated in combination with checkpoint inhibitors in solid tumors. Evelo’s pipeline also features earlier‐stage candidates aimed at addressing unmet needs in asthma, inflammatory bowel disease and additional oncology and inflammation settings. Clinical trials are under way across multiple sites in the United States and Europe, underscoring the potential breadth of Evelo’s therapeutic platform.
Founded in 2016 and headquartered in Cambridge, Massachusetts, with research operations in London, Evelo Biosciences emerged from academic collaborations in immunology and microbiome science. The company has advanced quickly through preclinical and clinical stages, establishing partnerships with leading research institutions and pharmaceutical collaborators to accelerate the development and commercialization of its biologic candidates. Its integrated R&D infrastructure spans discovery, translational research and clinical development.
Under the leadership of Chief Executive Officer James Monical, Evelo’s management team brings deep experience in biotechnology, immunology and commercial strategy. The company’s board and scientific advisory panels include experts in gut biology, clinical development and regulatory affairs. Evelo’s mission is to transform patient care by delivering safe, easy‐to‐administer biologic therapies that leverage the intersection of microbiome science and immunology.
AI Generated. May Contain Errors.
Free EVLO Stock Alerts